- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
Hand-foot syndrome induced by Pembrolizumab for non-small cell lung cancer (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2365; HFS has been described in the literature as an uncommon side effect of many anti-tumor drugs including pembrolizumab but always in combination with other drugs such as capecitabine, lenvatinib and anlotinib. There are no reports in literature concerning the development of HFS as side effect of pembrolizumab in monotherapy, thus our report may help researcher to improve the side effect profile of the immunotherapeutic agent that is nowadays considered a novel and encouraging tool against cancer.
- |||||||||| Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Enrollment change, Combination therapy: EMERALD-3: Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC (clinicaltrials.gov) - Aug 29, 2023 P3, N=725, Recruiting, There are no reports in literature concerning the development of HFS as side effect of pembrolizumab in monotherapy, thus our report may help researcher to improve the side effect profile of the immunotherapeutic agent that is nowadays considered a novel and encouraging tool against cancer. N=525 --> 725
- |||||||||| Opdivo (nivolumab) / BMS, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open: Neoantigen Derived DCs as Cancer Treatment (clinicaltrials.gov) - Aug 25, 2023 P1, N=12, Recruiting, Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Outcome of initial lenvatinib treatment in patients with unresectable anaplastic thyroid cancer. (Pubmed Central) - Aug 24, 2023 Two patients, who showed a reduction with lenvatinib, underwent conversion surgery, which prolonged the prognosis in terms of avoiding events, such as asphyxia, fistula and hemorrhage due to tumor growth; however, the surgical margins were positive, indicating that complete remission was impossible even if surgical resection was performed. Therefore, starting with lenvatinib treatment and identifying a therapeutic drug based on genomic analysis is an acceptable treatment strategy for ATC while halting the disease progression.
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Metastases: Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC) (clinicaltrials.gov) - Aug 24, 2023 P1, N=11, Active, not recruiting, Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||||||||| Stivarga (regorafenib) / Bayer, Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Retrospective data, Journal, Adverse events: Cardiovascular toxicities following the use of tyrosine kinase inhibitors in Hepatocellular Cancer Patients: A Retrospective, Pharmacovigilance Study. (Pubmed Central) - Aug 23, 2023 A total of 4708 cardiac AEs reports of sorafenib, regorafenib, lenvatinib and cabozantinib were identified...Analysis of FAERS data provides a precise profile on the characteristics of cardiac AEs associated with different TKI regimens. Distinct monitoring and appropriate management are needed in the care of TKI recipients.
- |||||||||| Safety and Efficacy of Stereotactic Radiosurgery with Concurrent Targeted Systemic Therapy for Brain Metastases (Hall B2; In Person Only; Screen: 11) - Aug 22, 2023 - Abstract #ASTRO2023ASTRO_663;
Although heterogeneous, patients treated with SRS/SRT and ongoing CNS-active targeted systemic therapies have on average >6 month intracranial PFS and little evidence of significant toxicity. We observed <6% G2+ radiation necrosis for this cohort, and no particular class of agent was associated with a significantly higher rate of G2+ radiation necrosis.
- |||||||||| zabinostat (CXD101) / IngenOx Therap, Nuance Biotech
Enrollment open, Checkpoint inhibition: CXD101 in Immunotherapy-related Liver Cancer (clinicaltrials.gov) - Aug 22, 2023 P2, N=44, Recruiting, Trial completion date: Jan 2025 --> Oct 2024 | Trial primary completion date: Jan 2025 --> Oct 2024 Not yet recruiting --> Recruiting
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: circFAM134B is a key factor regulating reticulophagy-mediated ferroptosis in hepatocellular carcinoma. (Pubmed Central) - Aug 21, 2023 In the current study, we found that the homologous circular RNA (circRNA) of the family with sequence similarity 134, member B (FAM134B), hsa_circ_0128505 (was abbreviated as circFAM134B in the present study), was identified to specifically target ER-phagy to promote lenvatinib (LV)-induced ferroptosis using reactive oxygen species (ROS), Fe, malondialdehyde (MDA), and western blot (WB) assays in HCC cells...circFAM134B was confirmed as a sponge that competitively interacted with PABPC4, thereby influencing FAM134B mRNA nonsense decay. Our results provide novel evidences and strategies for the comprehensive treatment of HCC.
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical, Journal, Metastases: Tumor Radiomic Features on Pretreatment MRI to Predict Response to Lenvatinib plus an Anti-PD-1 Antibody in Advanced Hepatocellular Carcinoma: A Multicenter Study. (Pubmed Central) - Aug 21, 2023 Furthermore, radiomic features were associated with overall survival and progression-free survival both in the training and validation cohorts, but modified albumin-bilirubin grade and neutrophil-to-lymphocyte ratio were not. Radiomic features extracted from pretreatment MRI can predict individualized objective response to combination therapy with lenvatinib plus an anti-PD-1 antibody in patients with unresectable or advanced HCC, provide incremental predictive value over clinicopathologic features, and are associated with overall survival and progression-free survival after initiation of this combination regimen.
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, Metastases: Lenvatinib for Advanced Bone and Soft Tissue Sarcoma (clinicaltrials.gov) - Aug 21, 2023 P2, N=60, Recruiting, Radiomic features extracted from pretreatment MRI can predict individualized objective response to combination therapy with lenvatinib plus an anti-PD-1 antibody in patients with unresectable or advanced HCC, provide incremental predictive value over clinicopathologic features, and are associated with overall survival and progression-free survival after initiation of this combination regimen. Not yet recruiting --> Recruiting
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Enrollment change, Surgery, Metastases: Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer (clinicaltrials.gov) - Aug 16, 2023 P2, N=3, Active, not recruiting, In this article, lenvatinib, one of the most commonly used MKIs in HCC, is chosen to be reviewed. Recruiting --> Active, not recruiting | N=24 --> 3
- |||||||||| livmoniplimab (ABBV-151) / AbbVie, budigalimab (ABBV-181) / AbbVie
Enrollment open, Adverse events, Checkpoint inhibition: LIVIGNO-1: Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - Aug 15, 2023 P2, N=120, Recruiting, The findings describe a novel regulatory axis, lnc-ZEB2-19/TRA2A/RSPH14, downregulating the nuclear factor kappa B to inhibit HCC progression and LR. Not yet recruiting --> Recruiting
- |||||||||| Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Trial primary completion date, Metastases: ZSAB-TransGOLP: Tislelizumab?Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer (clinicaltrials.gov) - Aug 15, 2023 P2, N=40, Active, not recruiting, Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2022 --> Jul 2023
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Sophoridine derivative 6j inhibits liver cancer cell proliferation via ATF3 mediated ferroptosis. (Pubmed Central) - Aug 14, 2023 Further study revealed that compound 6j upregulated the expression of ATF3 via ER stress and knockdown of ATF3 by RNA interference attenuated 6j induced ferroptosis and cell proliferation inhibition. This study would provide new insights for the design of ferroptosis inducers and the development of anti-liver cancer drugs.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date, Metastases: MK-3475-A70: Pembrolizumab and Lenvatinib in Advanced Cervical Cancer (clinicaltrials.gov) - Aug 14, 2023 P2, N=35, Recruiting, These results imply that the dosage of lenvatinib for pediatric patients may need to be augmented in order to attain the desired clinical outcome. Trial completion date: Jul 2023 --> Jul 2024 | Trial primary completion date: Jul 2023 --> Jul 2024
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD), simridarlimab (IBI-322) / Innovent Biologics
Biomarker, New trial, Combination therapy, Real-world evidence, Real-world: Real-World Study on the Efficacy of IBI-322 in Combination With Lenvatinib for the Treatment of Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov) - Aug 14, 2023 P=N/A, N=160, Not yet recruiting,
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Efficacy and safety of transarterial chemoembolization combined with lenvatinib, programmed death-1 inhibitor, and iodine-125 seed brachytherapy for hepatocellular carcinoma with portal vein tumor thrombosis. (Pubmed Central) - Aug 13, 2023 Recruiting --> Active, not recruiting A combination therapy of TACE, lenvatinib, programmed death-1 inhibitor, and I125 seed brachytherapy significantly improve OS, PFS, and DCR and show better survival prognosis for HCC patients accompanied by PVTT.
- |||||||||| Clinical guideline, Journal: SEOM SOGUG clinical guideline for treatment of kidney cancer (2022). (Pubmed Central) - Aug 9, 2023
In cases that have an intermediate IMDC and poor prognosis, the combination of ipilimumab and nivolumab has demonstrated superior OS compared to sunitinib...When there is progression following initial immunotherapy-based treatment, we recommend treatment with an antiangiogenic tyrosine-kinase inhibitor. While no clear sequence can be advocated, medical oncologists and patients should be aware of the recent advances and new strategies that improve survival and quality of life in the setting of metastatic RC.
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: Phase II Study of Concurrent Lenvatinib and Radiotherapy for Advanced HCC (clinicaltrials.gov) - Aug 9, 2023 P2, N=64, Active, not recruiting, While no clear sequence can be advocated, medical oncologists and patients should be aware of the recent advances and new strategies that improve survival and quality of life in the setting of metastatic RC. Recruiting --> Active, not recruiting | Trial completion date: May 2023 --> Sep 2023 | Trial primary completion date: May 2022 --> Aug 2022
- |||||||||| Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Journal, Real-world evidence, Real-world, Metastases: Beyond atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: overall efficacy and safety of tyrosine kinase inhibitors in a real-world setting. (Pubmed Central) - Aug 7, 2023 Median PFS rates were 2.6, 4.4, and 2.8?months in sorafenib-, lenvatinib-, and cabozantinib group, respectively...Regorafenib was associated with better OS and OGS rates compared to other TKI. These data need to be confirmed in prospective comparative studies.
|